Zealand Pharma reprimanded by Danish watchdog following sale of rescue pen to Novo Nordisk
The biotech company classified information as internal knowledge too late when negotiating a deal with Novo Nordisk, says the Danish Financial Supervisory Authority.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Zealand Pharma did not do an adequate job preventing the potential exploitation of internal knowledge regarding the buying and selling of shares while the company was negotiating rights for rescue pen Zegalogue with Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
